Peptides Promised a Shortcut. The Research Is Starting to Back It Up.
-
Click here to listen to this article - Share via
Dr. Amir Kalantar has spent the past several years watching peptide medicine evolve from a niche area of research into one of the most closely watched areas of modern medicine. In this exclusive conversation, he explains why peptide medicine has moved beyond a trend and started to look more like a broader therapeutic platform. “I was watching a therapeutic platform develop,” he says of his early interest in the field. Semaglutide and tirzepatide, in his telling, were the tipping point: “They showed us that a peptide can do much more than move a number on a lab test. It can change the trajectory of a patient’s health.”
Peptides have spent the last few years living something of a double life. On social media, they’re a wellness trend, promoted for weight loss, recovery, and vague promises of looking and feeling younger. In clinical research, they’re something more specific: a fast-growing category of therapies built on molecules precise enough to target a single biological pathway rather than blunt an entire system.
That gap between hype and evidence has been closing faster than most people realize. Semaglutide and tirzepatide, originally developed for diabetes and weight management, have gone on to show measurable effects on cardiovascular risk and sleep apnea in large clinical trials. A new generation of triple-receptor agonists, led by retatrutide, is already producing weight loss results once associated mainly with metabolic surgery. And peptides once dismissed as internet fads, like BPC-157, are starting to generate small but real human data.
None of this means every peptide on the market is proven, or that patients should treat these molecules casually. But it does mean the conversation has shifted. Peptide medicine is no longer just a promise. It’s becoming a body of evidence, and the physicians practicing in the field are increasingly the ones drawing the line between what’s established, what’s emerging, and what’s still just marketing.
To make sense of where the science actually stands, we spoke with Dr. Amir Kalantar, co-founder and CEO of The Peptide Doctors. His background also includes extensive experience in dermatology and clinical research, and he serves as medical director of a skincare line. Below is an edited transcript of our conversation.
THE Q&A
Q: Peptides have become one of the biggest wellness trends over the past few years. What’s driving the surge in interest, and is the science finally catching up to the hype?
A: I think the biggest change is that patients no longer want to be passive participants in their health. For generations, medicine was largely reactive. Disease appeared, then we treated it. Today, more people are asking, “What can I do now to change where my health is going five, ten, or twenty years from now?” We went from GLP-1 receptor agonism to dual receptor therapy with tirzepatide, and now to triple receptor agonism with retatrutide. We are moving from asking whether peptides work to asking how many different biological systems we can intelligently influence with them. I don’t think peptides are simply a wellness trend anymore. I think we are watching a therapeutic platform mature in real time.
Q: Which peptides currently have the strongest clinical evidence behind them, and which ones do you think are receiving more attention than the research supports?
A: Semaglutide and tirzepatide currently have the deepest clinical evidence, and I think they have completely changed what people expect from metabolic medicine. These are no longer drugs we should think about solely in terms of weight loss. What started as a weight loss revolution has become a metabolic health revolution. BPC-157 is earlier in its development, but I think it is important to describe the evidence accurately rather than saying there is no human data. In one published knee pain series, 11 of 12 patients receiving BPC-157 alone reported significant improvement. These are small studies, but they are human signals, and they are exactly the type of signals that justify larger, more rigorous investigation. Today’s emerging therapy can become tomorrow’s standard of care. That’s how medicine progresses.
Q: Retatrutide has become one of the most anticipated next-generation weight-loss drugs, even before FDA approval. What makes it different from semaglutide and tirzepatide?
A: Semaglutide primarily targets GLP-1. Tirzepatide targets GLP-1 and GIP. Retatrutide targets GLP-1, GIP, and the glucagon receptor. We have essentially gone from one metabolic signal, to two, and now to three within a single molecule. Retatrutide is not simply an attempt to make a stronger appetite suppressant. It represents a more sophisticated attempt to treat the biology of obesity from several directions at once. Lilly reported that participants receiving 12 mg in the Phase 3 TRIUMPH-1 trial lost an average of 28.3% of their body weight at 80 weeks. Nearly half achieved at least 30% weight loss. In TRIUMPH-4, participants with obesity and knee osteoarthritis receiving the 12 mg dose lost an average of 28.7% at 68 weeks, with substantial improvement in knee pain as well. When a medication begins producing average weight loss in a range historically associated with metabolic surgery, the entire treatment paradigm changes. A molecule manufactured for a pharmaceutical trial and a vial purchased anonymously online should never be assumed to be the same thing. Innovation this powerful should make people more interested in medical supervision, not less.
Inside the Viral Tanning Peptide That Accidentally Created Vyleesi’s FDA-Approved Low Sex Drive Drug
Unverified “sunless tanning” injections are exploding across social media, but their real scientific legacy isn’t a dark complexion. Here is how Melanotan’s unexpected side effect yielded a first-of-its-kind treatment for female libido.
Q: Beyond weight loss, what have semaglutide and tirzepatide taught us about the future of peptide therapies?
A: The biggest lesson is that obesity was never simply about body weight. Metabolism touches almost every organ system. In the SELECT trial, more than 17,000 adults with established cardiovascular disease and overweight or obesity, but without diabetes, were studied. Semaglutide reduced the incidence of major cardiovascular events by about 20% relative to placebo. Tirzepatide gave us another striking example in obstructive sleep apnea. In randomized trials involving adults with obesity and moderate to severe obstructive sleep apnea, it improved apnea severity, body weight, hypoxic burden, and several other clinically meaningful measures. Change the metabolic environment of the body, and you can potentially change diseases that we once thought about as completely separate problems. Semaglutide and tirzepatide are not the end of the peptide story. I think they are the proof of concept for what comes next.
Q: BPC-157 has gained a massive following online for injury recovery and gut health despite limited human data. Where do you see genuine promise, and where should patients be cautious?
A: BPC-157 is one of the molecules I find particularly exciting because it addresses something patients care deeply about and medicine still has room to improve: recovery and tissue repair. BPC-157 resonates because it taps into one of the most exciting frontiers in medicine: helping the body repair itself more effectively. In a published retrospective knee pain series, 11 of 12 people receiving BPC-157 alone reported significant improvement. In a small study of 12 women with treatment resistant interstitial cystitis, all participants reported improvement following local BPC-157 treatment, with 10 reporting complete symptom resolution. A 2025 pilot administered intravenous BPC-157 to two adults at doses up to 20 mg and reported no adverse effects within the laboratory and clinical parameters evaluated. Small human signals are not the finish line, but they can be the starting line. I would strongly discourage anyone from buying an injectable product from an anonymous research website and experimenting on themselves. Being excited about an emerging therapy and using it responsibly can absolutely go hand in hand.
Q: Growth hormone peptides like CJC-1295 and Ipamorelin are often marketed for anti-aging, recovery and performance. What does the current evidence actually support?
A: The growth hormone pathway is fascinating because it sits at the intersection of body composition, recovery, metabolism, sleep, and aging. In healthy adults, researchers found sustained, dose dependent increases in growth hormone and IGF-1 after administration. Another study found that CJC-1295 increased mean and trough growth hormone secretion and IGF-1 while preserving pulsatile growth hormone release. That matters because we are not talking about a purely theoretical mechanism. We can demonstrate the biological signal in humans. Where I think the terminology sometimes gets ahead of us is the word “anti-aging.” I would rather talk about healthy aging, recovery, body composition, and physiological optimization, because those are things we can actually define and measure. The goal of optimization should not be to push every hormone as high as possible. The goal should be better regulated biology.
Q: Many patients now come in asking for a specific peptide they saw on TikTok or Instagram. How do you separate evidence-based medicine from social media trends during those conversations?
A: I actually love when patients come in curious. Social media has made people more engaged with metabolism, longevity, recovery, body composition, and their own physiology. That curiosity is not something I want to shut down. The first question I ask is not, “Which peptide do you want?” It is, “What are we trying to accomplish?” Good peptide medicine should be measurable medicine. Curiosity can start on TikTok. The medical decision should happen in the exam room.
Q: Counterfeit and gray-market peptides have become a growing concern. What should consumers know before purchasing peptide therapies, and what red flags should they look for?
A: This may be the most important consumer issue in the peptide space. FDA has documented fraudulent products marketed as compounded semaglutide and tirzepatide, including products carrying pharmacy information that did not correspond to the pharmacy that supposedly compounded them. FDA also warns that illegally marketed products can contain the wrong ingredient, too little or too much active ingredient, no active ingredient, or potentially harmful ingredients. One of the clearest red flags is a vial labeled “research use only” or “not for human consumption” that is nevertheless being marketed directly to consumers with instructions for self administration. The peptide revolution will only be as credible as the medicine surrounding it. The physician, the pharmacy, and the supply chain all matter.
Q: If someone who is otherwise healthy asked you whether peptides are worth exploring for longevity or health optimization, what would your advice be?
A: I don’t think lifestyle and peptide medicine are competing philosophies. Lifestyle is the foundation. What excites me about longevity medicine is the shift from diagnosis to trajectory. The medicine of the past waited for disease. I think the medicine of the future will increasingly ask where your health is heading before you get there. Lifestyle gives us the foundation. Precision medicine gives us leverage. Peptides may become one of the most important tools we have for combining the two. That, to me, is the future of health optimization.
THE TAKEAWAY
Kalantar’s larger point is one he returns to throughout the conversation: peptides aren’t a shortcut around taking care of yourself, they’re a way to make that care more precise. “Healthspan is ultimately the metric that matters,” he says. “The goal is not simply to extend life. It is to extend the part of life in which you are healthy, independent, and functioning at a high level.”
Whether that promise holds up will depend on the data still to come, and on patients getting these therapies through physicians rather than anonymous vials online. But for a field that started as a wellness-forum curiosity, the science is no longer playing catch-up. As Kalantar puts it: “The wellness world noticed peptides early. Now mainstream medicine is beginning to understand why.”
Driven by GLP-1 shortages and FDA compounding restrictions, a multi-billion-dollar gray market for injectable peptides exploded online. The four words printed on those vials should stop you cold.
Disclaimer
This interview has been edited for length and clarity. Patients considering peptide therapy should consult a licensed physician; several molecules discussed, including retatrutide, remain investigational and are not FDA-approved. Dr. Kalantar is co-founder and CEO of The Peptide Doctors, and the professional background and credentials described in this piece are based on his own account.
